sorafenib has been researched along with loratadine in 1 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (loratadine) | Trials (loratadine) | Recent Studies (post-2010) (loratadine) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 1,317 | 462 | 339 |
Protein | Taxonomy | sorafenib (IC50) | loratadine (IC50) |
---|---|---|---|
Cytochrome P450 2C19 | Homo sapiens (human) | 0.016 | |
Histamine H1 receptor | Homo sapiens (human) | 0.23 | |
5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.245 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.1717 | |
Bile acid receptor | Homo sapiens (human) | 3.07 | |
Sodium-dependent neutral amino acid transporter B(0)AT2 | Homo sapiens (human) | 4 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for sorafenib and loratadine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |